Status:
COMPLETED
Noninferiority Oral Tranexamic Acid vs Intravenous Administration in Total Hip Arthroplasty
Lead Sponsor:
University of Liege
Conditions:
Hemorrhage Postoperative
Total Blood Loss
Eligibility:
All Genders
18-90 years
Phase:
PHASE4
Brief Summary
To find noninferiority relationship between oral and intravenous administration of tranexamic acid on peroperative and postoperative blood loss and serum concentration during primary total hip arthrop...
Detailed Description
Tranexamic acid is an anti-fibrinolytic drug, recommended in total hip arthroplasty to reduce peroperative and postoperative hemorrhagic complications. The original character of our study lies in the ...
Eligibility Criteria
Inclusion
- \- ASA physical status 1, 2 and 3 scheduled for primary total hip arthroplasty
Exclusion
- Renal failure with serum creatinine level higher than 1,40 mg/dL
- Thromboembolic events in last 12 months before surgery
- Pregnancy
- Congenital or acquired coagulation diseases
- History of gastric surgery that could lead to malabsorption
- Diabetic gastro-paresis
Key Trial Info
Start Date :
January 1 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 14 2022
Estimated Enrollment :
230 Patients enrolled
Trial Details
Trial ID
NCT04691362
Start Date
January 1 2021
End Date
December 14 2022
Last Update
December 15 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
CHU de Liège
Liège, Belgium, 4000